Zetagen Therapeutics Secures Composition-of-Matter Patents from USPTO for Novel Breast Cancer Platform
(Composition-of-matter and compound patents are valuable forms of intellectual property within the pharmaceutical industry)
Article content
Article content
Expanded Protection & Strategic Value – These patents underscore the company's defensible innovation, strengthening its appeal to investors, partners, and future acquirers
Article content
SYRACUSE, N.Y. — Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via intratumorally administration, for primary and metastatic breast cancers, announced today they have successfully secured the foundational Composition-of-Matter patents and claims from the USPTO for their proprietary breast cancer platform.
Article content
'Securing these allowances and composition-of-matter patents for our intratumorally administered breast cancer therapeutics represents a strategic leap forward in our mission to redefine oncologic care,'
Article content
said Joe C. Loy, CEO of Zetagen Therapeutics
Article content
. 'This latest patent protects the molecular uniqueness of our drug ZetaPrime™ and affirms the disruptive potential in our pursuit to minimize off target side effects of conventional chemotherapeutics. We are proud to advance precision therapies designed to target tumors directly and deliver meaningful hope to patients with limited options.'
Article content
Zetagen Therapeutics has built a robust intellectual property portfolio anchored in its groundbreaking discoveries in intratumorally drug administration for both primary and metastatic breast cancer. The company's IP estate—which now includes multiple composition-of-matter patents— focuses on proprietary and established molecules designed to be delivered directly into tumors, reducing systemic toxicity and off-target side effects. This precision method not only protects healthy tissue but also holds the potential to significantly improve survival outcomes by enhancing therapeutic efficacy at the site of disease. Zetagen' s growing suite of patents underscores its commitment to redefining standards of care and advancing targeted oncology innovation.
Article content
said Bryan S. Margulies, Ph.D., CSO of Zetagen Therapeutics.
Article content
'By securing these patents, we validate the unique molecular design of our compounds and strengthen our pursuit of transformative therapies for underserved patient populations.'
Article content
Zetagen has enlisted Foley & Lardner LLP as its intellectual property counsel and maintains a collaborative professional relationship with Steve Maebius, Esq. Foley & Lardner LLP is a prominent law firm with global reach and specialized expertise in Life Sciences intellectual property and strategic counsel.
Article content
About ZetaMet™ (Zeta-BC-003) – Lead Drug Candidate:
Article content
ZetaMet™ is a groundbreaking molecular pathway drug, targets metastatic breast cancer in bone, ceasing lytic activity, inhibits pain, and regenerates new bone all via locoregional administration, 30-minute outpatient procedure, without systemic limitation, minimizing skeletal related events (SRE) while increasing survival rates.
Article content
ZetaMet™ has been awarded 2x FDA Breakthrough Designations and has been approved in the treatment of 8x Compassionate Use stage 4 cancer patients in the US and Canada.
Article content
ZetaMet™ has demonstrated cross-species efficacy at consistent concentrations, with findings published in several peer-reviewed journals—underscoring its translational promise from lab to clinic. Notably, these individuals had previously failed to respond to standard treatments such as chemotherapy, surgery, and radiation.
Article content
Zetagen has successfully completed enrollment of phase 2a clinical trial for the treatment of metastatic breast cancer to the spine, University of British Columbia, preliminary results available upon request and full study results anticipated November 2025.
Article content
ZetaMast™ is a proprietary drug-eluting hydrogel carrier designed for locoregional administration, controlled release of small molecules in treatment of multifocal, unresectable, liver metastases from breast cancer with potential to increase survival rates.
Article content
Zetagen has completed preclinical studies, drug elution refinement, toxicity testing and a dose optimization study, results published in peer-review journal PLOS-One. Zetagen plans to file an IND with the FDA this fall and upon approval conduct a Phase 1b dose escalation study early 2026.
Article content
About ZetaPrime™ (Zeta-PBC-007)
Article content
ZetaPrime™ is a neo-adjuvant treatment for primary HR+ breast cancer, engineered for a locoregional administration following diagnosis. Utilizing a proprietary hydrogel-like lipid carrier, formulation enables controlled release of two small molecules— one being our novel molecular entity, and the ability to deliver other companies CDK4 or CDK4/6 protein inhibitor and any anticancer therapeutic. Designed for solubility within adipose tissue, approach targets primary breast cancer, aiming to mitigate off-target effects, reduce necessity for lumpectomies and mastectomies, postpone radiation exposure, and enhance patient survival.
Article content
About Zetagen Therapeutics
Article content
Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company, dedicated to developing proprietary carriers delivering tumoricidal therapies intratumorally via a singular injection for primary and metastatic breast cancer, minimizing patient side effects and postponing palliative radiation with the potential to increase survival rates.
Article content
The company's 'Zeta' platform encompasses the following breast cancer drug candidates ZetaMet™ (Zeta-BC-003), ZetaMast™ (Zeta-MBC-005) and (NEW) ZetaPrime™ (Zeta-PBC-007). To learn more, visit www.zetagen.com.
Article content
Zetagen will attend the San Antonio Breast Cancer Symposium (SABCS) in December.
Article content
Forward-Looking Statements
Article content
This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
20 minutes ago
- Globe and Mail
Top AI Stocks to Add to Your Portfolio for Healthy Returns
An updated edition of the July 3, 2025, article. Artificial Intelligence (AI) is transforming industries by powering machines to analyze data, recognize patterns and make decisions. The rapid deployment of generative AI (Gen AI), agentic AI, and multi-modal learning supported by advanced hardware like GPUs and TPUs is fueling innovation across healthcare, finance, robotics, cybersecurity and e-commerce. AI now powers chatbots, diagnostics, fraud detection and autonomous systems, boosting agility while simultaneously improving efficiency. Microsoft MSFT backed Open AI recently introduced GPT-5, which offers multi-modal understanding across text, images, audio and more. The latest model offers stronger reasoning, emotional intelligence, persistent memory for personalized interactions and an autonomous task-performing agent. AI is evolving rapidly, with Meta Platforms ' META latest AI systems boasting self-improvement without human intervention, pushing AI toward superintelligence. Meanwhile, Baidu plans to release an advanced reasoning AI model, along with upgrades to Ernie 5.0, spicing up the AI race between the United States and China. Per IDC, global spending on AI is expected to be $307 billion in 2025, expanding to $632 billion by 2028. Per Gartner, global Gen AI spending is expected to hit $644 billion in 2025, indicating 76.4% growth over 2024. U.S. tech giants, including Microsoft, Adobe, Alphabet and Meta Platforms, have been at the forefront of bringing remarkable advances to AI technology, well supported by powerful AI chips from NVIDIA NVDA and Broadcom AVGO. Powerful hardware is helping complex AI applications like computer-aided design (CAD), and product lifecycle management (PLM) is driving prospects of companies like PTC PTC. Alphabet GOOGL is infusing AI into its search business in order to attract more users, while Meta Platforms' focus on integrating AI into its platforms is driving user engagement. Both initiatives are driving ad revenue growth. We believe that the rapid deployment of AI technology and huge spending on its development efforts offer significant growth opportunities for investors. Our Artificial Intelligence Screen is an invaluable source for identifying AI stocks with massive growth prospects. Explore 30 cutting-edge investment themes with Zacks Thematic Screens and uncover your next big opportunity. 3 AI Stocks to Buy Right Now PTC is benefiting from strong demand for its PLM and CAD solutions. This Zacks Rank #1 (Strong Buy) company is generating significant recurring revenues, driven by its broad product portfolio, and solid investment in cloud and SaaS offerings. You can see the complete list of today's Zacks #1 Rank stocks here. Solid demand for precision designing, as well as complex prototyping and digitalization, is expected to drive the demand for PTC's 3D-CAD offerings in the automotive, aerospace, manufacturing, healthcare and defense verticals. Increasing demand for PTC's major technology platforms, including Creo, Windchill, ThingWorx and Vuforia Studio, is expected to drive top-line growth. PTC has lifted the fiscal 2025 Annual Recurring Revenue guidance at constant currency from 7-9% to 8-9%. The company is emphasizing continuing momentum in go-to-market and AI product initiatives. Revenues for fiscal 2025 are projected to be $2,570-$2,630 million, indicating a year-over-year rise of 12-14%. Non-GAAP earnings are now estimated to be $6.63-$7.03, suggesting a rally of 31-38%. Broadcom is benefiting from an expanding portfolio, a rich partner base, a solid VMware business, a strong balance sheet and an impressive free cash flow. Custom AI accelerators (XPUs), which are a type of application-specific integrated circuit (ASICs) chips, are necessary to train Gen AI models, and they require complex integration of compute, memory and I/O capabilities to achieve the necessary performance at lower power consumption and costs. Strong demand for Broadcom's ASICs is driving top-line growth. AVGO sees massive opportunities in the AI space as its three hyperscaler customers have started to develop their XPUs. It believes that by 2027, each of AVGO's three hyperscalers plans to deploy 1 million XPU clusters across a single fabric. Strong demand for AI networking revenues, which skyrocketed 170% year over year, represented 40% of AI revenues. This Zacks Rank #2 (Buy) company's networking portfolio, which comprises Tomahawk switches, Jericho routers and NICs, is helping Broadcom gain market share among hyperscalers. Broadcom's focus on delivering AI-powered, proactive security to stay ahead of evolving cyber threats has been noteworthy. Microsoft is benefiting from its strategy of infusing AI into its applications. AI assistants, including Microsoft 365 Copilot for commercial customers and the consumer Copilot in Windows, reached 100 million monthly active users in fourth-quarter fiscal 2025. The integration of AI capabilities across this Zacks Rank #2 company's product portfolio is driving revenues per user for Microsoft 365 commercial cloud products. In terms of cloud infrastructure, Microsoft has transformed every Azure region into an AI-first environment with liquid cooling capabilities, positioning itself at the forefront of the AI infrastructure wave. Microsoft has added more than two gigawatts of datacenter capacity over the past 12 months, now operating more than 400 datacenters across 70 regions globally, above any other cloud provider. Microsoft's early and aggressive investments in AI, particularly through its partnership with OpenAI, have positioned Azure as the preferred platform for AI workloads, attracting both startups and enterprises seeking to leverage cutting-edge AI capabilities. Microsoft's deep partnership with OpenAI and its Azure AI Foundry platform has already attracted more than 14,000 customers building generative AI models and intelligent agents. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Microsoft Corporation (MSFT): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Broadcom Inc. (AVGO): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report PTC Inc. (PTC): Free Stock Analysis Report Meta Platforms, Inc. (META): Free Stock Analysis Report
Globe and Mail
20 minutes ago
- Globe and Mail
PayPal vs. Block: Which Fintech Stock Is the Better Buy Right Now?
PayPal Holdings PYPL and Block XYZ have long been at the center of fintech investing. Both companies are reshaping digital payments and commerce, but they approach the opportunity from different angles: PayPal with its global two-sided payments and commerce platform, and Block with its dual ecosystem of Square and Cash App. Their latest second-quarter 2025 earnings highlight diverging strengths — PayPal's improving profitability and platform innovation versus Block's network expansion and product velocity. Let's weigh the pros and cons of each to find out which deserves a spot in your portfolio. The Case for PayPal PayPal delivered a solid second quarter, with revenues up 5% year over year to $8.3 billion, Total Payment Volume ('TPV') climbing 6% and non-GAAP EPS growing 18% to $1.40. Transaction margin dollars, excluding interest on customer balances, rose 8%, underscoring the health of its core payments engine. Importantly, PayPal raised its full-year EPS and transaction margin dollar guidance, signaling confidence in sustained momentum. Strategically, PayPal is executing on four growth pillars: winning checkout, scaling omni and Venmo, driving payment services profitability, and investing in next-gen vectors like AI, ads and stablecoins. Venmo, in particular, grew revenues more than 20% year over year, with Venmo Debit Card monthly active account growth of more than 40% and Pay with Venmo TPV soaring 45%. The company is also rolling out PayPal World, connecting major wallets like Mercado Pago, NPCI's UPI and Tenpay Global to broaden its global reach. These initiatives strengthen its relevance in both e-commerce and offline retail while laying the groundwork for new revenue streams. That said, PayPal still faces challenges. While TPV rose 6%, payment transactions fell 5% as unbranded processing weighed on volumes. Engagement per user also slipped slightly, with payment transactions per active account on a trailing 12-month basis declining 4% year over year. Still, excluding low-margin processing, engagement improved. Compared to Block, PayPal offers greater global scale and a stronger branded checkout presence, but its growth profile is steadier rather than explosive. Investors seeking a combination of resilience, profitability and innovation may find PayPal's improving fundamentals more compelling. The Case for Block Block's second quarter was a story of strong gross profit growth but softer top-line performance. Revenues declined 2% year over year to $6.05 billion, missing expectations, but the gross profit rose 14% to $2.54 billion, with Cash App up 16% and Square up 11%. Adjusted operating income surged 38% with a margin of 22%, showing that scale and efficiency are starting to pay off. Block's strength lies in Cash App's momentum. With $1.5 billion in gross profit, Cash App continues to serve as a financial hub for younger customers, expanding into P2P, commerce, banking and bitcoin. The company introduced new products like Cash App Pools for group payments, Afterpay integrations and enhanced borrowing features — all deepening engagement. Meanwhile, Square is seeing double-digit GPV growth and rolling out innovations like Square AI and Tap to Pay on iPhone. Together, these ecosystems reinforce Block's ambition to be a comprehensive financial operating system. Still, Block's journey isn't without headwinds. Bitcoin remains a meaningful part of Block's strategy, but it also adds volatility. Competition is fierce, particularly in consumer payments, where PayPal and other global networks have more entrenched merchant acceptance. While Block's innovation velocity is impressive, it is still more U.S.-centric and reliant on Cash App's young demographic, leaving it somewhat narrower in scope than PayPal's global reach. How Do Zacks Estimates Compare for PYPL & XYZ? The Zacks Consensus Estimate for PayPal's 2025 sales and EPS implies a year-over-year increase of 3.97% and 12.04%, respectively. EPS estimates have been trending northward over the past month. Meanwhile, the consensus estimate for Block's 2025 sales calls for a year-over-year rise of 1.83%, while that for EPS suggests a 23.7% decline year over year. EPS estimates have also been trending southward over the past week. Valuation: PYPL vs. XYZ From a valuation perspective, we note that PayPal shares are trading cheap, as suggested by the Value Score of A. However, Block shares are currently overvalued, as implied by the Value Score of D. In terms of forward 12-month Price/Sales (P/S), PYPL stock is trading at 1.94X, below its three-year median, while Block is currently trading at 1.81X, which is ahead of its three-year median. Image Source: Zacks Investment Research Price Performance: PYPL vs. XYZ Over the past three months, shares of XYZ have outperformed PYPL and the S&P 500 composite. Conclusion: PayPal Has the Edge Right Now Both PayPal and Block posted strong Q2 results, but their paths diverge. PayPal is proving it can deliver steady, profitable growth while investing in next-generation commerce and global wallet connectivity. Block is firing on all cylinders in product innovation and engagement, but with greater volatility and earnings inconsistency. For investors deciding today, PayPal looks like a better buy, offering scale, profitability and resilience. Block remains a company worth holding, given its powerful ecosystems and long-term potential, but PayPal's execution and global positioning give it the edge right now. Estimate revisions and valuations also suggest the same. Currently, PYPL has a Zacks Rank #2 (Buy), while Block carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Block, Inc. (XYZ): Free Stock Analysis Report
Globe and Mail
30 minutes ago
- Globe and Mail
Citigroup's Card Delinquencies Rise: Will it Impact Asset Quality?
In a recent SEC filing, Citigroup Inc. 's C subsidiary, Citibank N.A., disclosed a rise in its credit card trust delinquency rates for July 2025 from June 2025. Nonetheless, both metrics remained under their pre-pandemic levels despite the recent uptick. For the period ending July 2025, the Citibank Credit Card Issuance Trust posted a delinquency rate of 1.42%, up modestly from 1.38% in June. Encouragingly, the figure remains below the 1.53% level seen in July 2019, before COVID-19 disruptions. Meanwhile, the trust's net charge-off rate eased to 2.07% in July from 2.12% in June, considerably lower than the 2.91% recorded in July 2019. Lending activity within Citibank's credit card trust showed some softness. Principal receivables in the trust decreased to $20.7 billion by the end of the period (July 2025) from $20.9 billion the previous month. The company's net credit loss (NCL) witnessed a compounded annual growth rate (CAGR) of 4.3% over the past four years ended in 2024. In the first half of 2025, NCL rose 2% year over year. Also, the company's provisions saw a CAGR of 38.9% from 2022 to 2024, with the rising trend persisting in the first half of 2025. Looking ahead, Citigroup's profitability may face headwinds from the continued rise in credit losses in its Branded Cards portfolio, wherein NCL rates are projected between 3.50% and 4% in 2025. At the end of 2024, branded cards NCL rates were 3.55%. Should economic conditions weaken further, losses may accelerate, prompting higher loan-loss provisions and pressuring earnings. With interest rates expected to stay elevated for longer, borrowers' repayment capacity will remain under strain. Coupled with the lingering effects of quantitative tightening, these dynamics suggest that Citigroup's asset quality is likely to remain under pressure in the near term. How Citigroup Stacks Up Against Peers in Card Delinquency U.S. credit card metrics were mixed in July, with delinquencies rising and net charge-offs falling. Following the industrywide trend, Capital One Financial COF and JPMorgan JPM credit card delinquency rates also increased, while net charge-off fell. Capital One's delinquency rate rose to 3.67% in July 2025 from 3.60% in June, while Capital One's net charge-off rate of 4.83% declined from 4.96% in the prior month. JPMorgan Issuance Trust delinquency rate ticked up to 0.86% in July from 0.84% in June. JPMorgan's net charge-off rate of 1.54% dropped from 1.69% in June and 2.21% six years ago. C's Price Performance, Valuation & Estimates Shares of Citigroup have gained 36.6% year to date compared with the industry 's growth of 23.2%. Image Source: Zacks Investment Research From a valuation standpoint, C trades at a forward price-to-earnings (P/E) ratio of 10.57X, below the industry's average of 14.47X. Price-to-Earnings F12M Image Source: Zacks Investment Research The Zacks Consensus Estimate for C's 2025 and 2026 earnings implies year-over-year rallies of 27.4% and 27.7%, respectively. The estimates for 2025 and 2026 have been revised upward over the past 60 days. Estimates Revision Trend Image Source: Zacks Investment Research Citigroup currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report Capital One Financial Corporation (COF): Free Stock Analysis Report
